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Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal haematopoietic stem cell disorder associated with a deficiency of multiple glycophosphatidylinositol (GPI)-linked antigens on haematopoietic cells. 1 The lack of GPI anchored proteins results from a somatic mutation of the phosphatidylinositol glycan complementation class A (PIG-A) gene. 2 PNH may occur at any age in children and adults up to 82 years of age and is seen most frequently in adults between 30 and 50 years of age. [3] [4] [5] The incidence of PNH is expected to be similar to that of aplastic anaemia (2-6 per million people) with which it shares similarities. 6 Usually, PNH takes a chronic course with a median survival of 10-15 years. 4 PNH is clinically characterized by the triad of intravascular haemolysis, cytopenias of varying severity and a tendency towards thrombosis. The detection of antigen-deficient populations of red cells, granulocytes, monocytes, lymphocytes and platelets by flow cytometry forms the diagnostic basis of PNH. 7 Depending on the clinical manifestations and immunphenotyping, the syndrome can be classified into haemolytic PNH with overt episodes of haemolytic anaemia, and hypoplastic PNH in which clones of GPIdeficient haematopoietic cells are detectable without apparent haemolysis. [5] [6] [7] Besides immunosuppressive treatment, therapy usually is supportive and the only curative option is an allogeneic stem cell transplant if an appropriate HLA-matched sibling donor is available. 8 Advantages of transplanting highly purified peripheral blood CD34+ cells are moderate acute organ toxicity, rapid engraftment and no need of prophylactic immunosuppression because GVHD prophylaxis is ensured by a T-cell depleted graft. 9, 10 We report a patient whose severe haemolysis and GPI deficiency diminished after the transplantation of highly purified CD34 positive blood stem cells from an HLA-identical sibling donor. Treatment of PNH using this kind of transplantation modality is first reported.
Patient and methods
A 46-year-old man was referred to our centre in July 2002. He had been diagnosed with PNH 18 months earlier after experiencing exhaustion, erectile dysfunction, anaemia and episodes of brownish urine in the morning. Since 1998 he had suffered from temporary thrombocytopenia, which retrospectively must be interpreted as the first manifestation of PNH. The diagnosis of PNH was confirmed in December 2000 by flow cytometric examination of the peripheral blood. Immunosuppressive treatment with CsA was initiated but no benefit occurred. Another attempt at therapy with prednisolone 100 mg daily led to slight reduction in haemoglobinuria but a significant increase in haemoglobin was not documented. The patient developed steroid-induced diabetes and because no significant benefit resulted from the steroids, therapy was terminated. With supportive iron therapy, iron deficiency was controlled but the haemolysis steadily increased, and in addition to gallstone formation, progressive splenomegaly was found. In view of the resistance to therapy and the fact that he had an HLA-identical brother, stem cell transplantation took place in July 2002 after conditioning with TBI (10 Gy divided into four fractions), anti-thymocyte-globulin (ATG) 40 mg/kg, cyclophosphamide 120 mg/kg and thiotepa 10 mg/kg (total doses). At the time of conditioning, the patient was experiencing exercise-induced weakness and constant haemoglobinuria. Ultrasound examination revealed splenomegaly (160 Â 66 mm), the haemoglobin was 8.2 g/dl, leucocytes 4.3/nl, platelets 157/nl. Parameters measuring haemolysis were markedly increased with a lactic dehydrogenase (LDH) of 3235 U/l and a total bilirubin of 3.63 mg/dl. Bone marrow aspirates cytologically demonstrated increased erythropoiesis, dysmorphic megakaryopoiesis and mature but reduced granulopoiesis. On chromosomal analysis a loss of Y-chromosomes was verified in 10 metaphases. After conditioning, which was well tolerated, the patient received 6.1 Â 10 6 /kg bodyweight CD34-positive cells with 0.81 Â 10 4 /kg bodyweight T-cells. Haematologic recovery was uneventful and engraftment was observed on day 12 (neutrophils41000/ ml, platelets420 000/ml). Neutropenic fever that lasted 4 days was resolved with standard broad-spectrum antibiotics combined with antiviral and antifungal treatment. Serology for common infections and blood cultures remained negative. In total, the patient received 18 erythrocyte concentrates, the last transfusion taking place 10 days before discharge from hospital. The LDH, increased 13-fold at the beginning of treatment, declined to nearly normal values at the end of the hospital stay (Figure 1 ). The patient was discharged 18 days after transplantation in good physical condition, with stable engraftment (Hb 9.6 g/dl, leucocytes 4.5/nl, platelets 41/nl), normalized parameters of haemolysis and absent haemoglobinuria. Bone marrow aspirates corroborated complete chimerism using PCR and chromosomal analysis which showed a normal karyotype. Flow cytometric analysis of the peripheral blood 40 and 100 days after transplant confirmed the absence of GPI deficiency in erythrocytes, monocytes and neutrophils. Interestingly, the CD59 surface antigen on lymphocytes could not be evaluated.
Discussion
Although allogeneic SCT is the only curative treatment for PNH, 8 experiences with SCT in PNH are limited. PNH is not a malignant condition and spontaneous remissions occur in about 15% of patients. 4 Furthermore, allogeneic SCT is associated with a high risk of acute transplantrelated mortality, Principally as a result of acute organ toxicity, graft failure, infectious complications and acute GVHD. Successful outcome after HLA-identical sibling donor SCT for PNH averages 60%. 11, 12 Some factors including cytopenias, a need for more than one treatment, and thrombocytopenia at diagnosis have been shown to be related to a poor survival. 5 The decision of whether to conduct allogeneic SCT in a PNH patient is quite difficult and may depend on the availability of a matched sibling donor and complications such as transfusion-dependent cytopenia refractory to immunosuppressive therapy, thrombotic events or evolution of a myelodysplastic syndrome. Allogeneic PBSCT with CD34-cell enrichment can prevent acute GVHD and chronic post transplant toxicity caused by immuneprophylaxis because grafts are indirectly T-cell depleted and, therefore, post transplant immunosuppression is not necessary. The reason for the intensified myeloablative conditioning therapy as for malignant diseases is to avoid graft failure due to rejection. In addition, although PNH is not a malignant disease, it is a clonal stem cell disorder with the potential for transforming into acute myeloid leukaemia, which makes myeloablative conditioning reasonable. Our experiences from patients with CML in the first chronic phase who were transplanted with CD34 purified stem cells from sibling donors suggest acceptable transplant-related morbidity and mortality, rapid engraftment and a low incidence of GVHD. 9, 10 Organ toxicity was moderate and the risk of developing life-threatening acute GVHD was markedly reduced by using this kind of transplantation. In our case, transplantation of purified blood CD34-positive cells after myeloablative conditioning was also confirmed as a safe treatment strategy for PNH and it proved to be associated with rapid engraftment, effective prevention of GVHD and capable of eradicating the PNH clone. Of interest is the fact that 40 and 100 days after transplantation, lymphocytes, thought to be of host origin, could not be evaluated by flow cytometry regarding their CD59 expression. It is possible that these cells are damaged as a result of ATG therapy during conditioning. However T-cell chimerism may be incomplete in the early phase after transplantation and becomes complete later after donor lymphocyte infusions (DLI). 10 An interesting feature is the question of whether to use donor lymphocyte add backs. On the supposition that PNH clones may have an intrinsic ability to autonomously expand even in a normal bone marrow environment, 13, 14 pre-emptive DLI could be a reasonable approach to maintain haematologic remission, assuming that there All-CD34-enriched peripheral blood SCT M Ditschkowski et al might exist a certain graft-versus-PNH-clone effect. However, this is a hypothetical suggestion, and to date there is no practical evidence for the eradication of a PNH clone by DLI. In conclusion we, for the first time, successfully treated a refractory, progressing case of PNH by allogeneic transplantation of peripheral blood CD34-positive cells from an HLA-identical sibling donor without prophylactic post transplant immunosuppression. This observation may provide a background for treatment studies for PNH which take advantage from innovative transplant modalities.
